GDF15: An emerging disease target and biomarker of metabolic diseases

Growth differentiation factor 15 (GDF15), a member of the transforming growth factor-β (TGF-β) superfamily, has garnered increasing attention for its involvement in metabolic regulation. This review aims to provide a comprehensive overview of the secretion mechanisms and functional roles of GDF15 in metabolic diseases (MD), with the goal of informing future clinical diagnostics, guiding biomarker discovery, and advancing personalized treatment strategies.

This review synthesizes findings from both experimental and clinical studies that investigate the physiological expression, regulatory mechanisms, and systemic actions of GDF15. Particular focus is placed on the GDF15-GFRAL-RET signaling axis and its influence on glucose and lipid metabolism, appetite regulation, and energy homeostasis across key metabolic organs and systems.

Numerous studies have established a robust correlation between serum GDF15 concentrations and a spectrum of MD. The GDF15-GFRAL-RET signaling pathway is responsible for modulating glucose and lipid metabolism, suppressing appetite, and maintaining energy homeostasis by integrating the actions of various tissue systems, such as the liver, adipose tissue, muscle, the central nervous system, and the peripheral sympathetic nervous system. Additionally, these regulatory effects are largely independent of appetite-regulating hormones such as leptin and glucagon-like peptide-1 (GLP-1), and they may exhibit coordinated effects.

GDF15 plays a key role in metabolic regulation and shows strong potential as a diagnostic biomarker and therapeutic target for MD. Continued research is needed to support its clinical application and guide the development of personalized treatment strategies.